Jacobs Levy Equity Management, Inc Reata Pharmaceuticals Inc Transaction History

Jacobs Levy Equity Management, Inc

  • $24.7 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$22.15 - $42.11 $492,771 - $936,821
-22,247 Reduced 18.86%
95,726 $3.64 Million
Q3 2022

Nov 15, 2022
BUY
$19.41 - $36.49 $2.29 Million - $4.3 Million
117,973 New
117,973 $2.97 Million

Others Institutions Holding RETA

# of Institutions
5
Shares Held
62.7K
Call Options Held
0
Put Options Held
0
View Full List

About REATA PHARMACEUTICALS INC

RETA Quotes by TradingView
  • Ticker RETA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,583,200
  • Description
  • Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...
More about RETA
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email